Caribou Biosciences Inc. (CRBU)
$1.57
$0.00 (0.00%)As on 04-Sep-2026 16:00EDT
Market cap
$168 Mln
Revenue (TTM)
$10 Mln
P/E Ratio
--
P/B Ratio
1.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-36.9
-
Debt to Equity
0
-
Book Value
$0.9
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
107,207,513
5 Years Aggregate
CFO
$-282.00 Mln
EBITDA
$-353.96 Mln
Net Profit
$-326.15 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Caribou Biosciences (CRBU)
| -1.3 | 4.7 | -21.5 | -16.9 | -35.6 | -44.6 | -- |
|
BSE Sensex*
| -10.0 | -3.5 | 2.6 | -5.6 | 5.0 | 5.5 | 10.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Caribou Biosciences (CRBU)
| 0.0 | -72.0 | -8.8 | -58.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Caribou Biosciences (CRBU)
|
1.6 | 168.3 | 10.0 | -103.4 | -793.9 | -93.9 | -- | 1.7 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Caribou Biosciences (CRBU)
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA... genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Read more
-
Co-Founder, CEO, President & Director
Dr. Rachel E. Haurwitz Ph.D.
-
Co-Founder, CEO, President & Director
Dr. Rachel E. Haurwitz Ph.D.
-
Headquarters
Berkeley, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Caribou Biosciences (CRBU)
What is the current share price of Caribou Biosciences Inc (CRBU) Today?
The share price of Caribou Biosciences Inc (CRBU) is $1.57 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Caribou Biosciences Inc (CRBU) has given a return of -35.61% in the last 3 years.
What is the current PB & PE ratio of Caribou Biosciences Inc (CRBU)?
Since, TTM earnings of Caribou Biosciences Inc (CRBU) is negative, P/E ratio is not available.
The P/B ratio of Caribou Biosciences Inc (CRBU) is 1.74 times as on 04-Sep-2026, a 67 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.01 |
1.23 |
2024 |
-0.96 |
0.57 |
2023 |
-4.96 |
1.38 |
2022 |
-3.85 |
1.27 |
2021 |
-13.57 |
2.34 |
What is the 52 Week High and Low of Caribou Biosciences Inc (CRBU)?
The 52-week high and low of Caribou Biosciences Inc (CRBU) are Rs 3.54 and Rs 1.38 as of 07-Sep-2026.
What is the market cap of Caribou Biosciences Inc (CRBU)?
Caribou Biosciences Inc (CRBU) has a market capitalisation of $ 168 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Caribou Biosciences Inc (CRBU)?
Before investing in Caribou Biosciences Inc (CRBU), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.